The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma
NCT ID: NCT00940823
Last Updated: 2018-03-13
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
238 participants
Study Classification
INTERVENTIONAL
Study Start Date
2005-07-31
Study Completion Date
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to compare the safety and efficacy of the Ahmed valve and the Baerveldt implant in treating refractory glaucoma. Eligible patients will be recruited from multiple study centers and randomized to a glaucoma drainage device for implantation. They will be followed long-term based upon outcome measures including intraocular pressure, glaucoma medication use, visual acuity, complications of the surgery and further treatments required.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Baerveldt (BGI) Valve Versus Ahmed(AGV) Valve in Management of Difficult Glaucoma Cases
NCT04215575
Glaucoma, Open-Angle
Glaucoma Secondary
Glaucoma, Neovascular
+1 more
COMPLETED
NA
Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma
NCT04542616
Glaucoma
COMPLETED
NA
Ahmed Versus Baerveldt Comparison Study
NCT00376363
Glaucoma
COMPLETED
NA
Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma
NCT00893490
Refractory Glaucoma
UNKNOWN
PHASE1
The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)
NCT02691455
Glaucoma
TERMINATED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Introduction:
The use of a glaucoma drainage device (GDD) is indicated in cases of refractory glaucoma not responsive to conventional medication, laser and surgical therapy. Most of these patients are at high risk for surgical failure, with serious concomitant ocular and systemic diseases. GDD's are increasingly being used to obtain low target intraocular pressures (IOP) in patients who have failed antimetabolite trabeculectomy or have active neovascular glaucoma.
Since Molteno's original design, several drainage devices have become commercially available for implantation. Currently, the two most commonly used devices are the Ahmed Glaucoma Valve (AGV) (New World Medical, Inc., Rancho Cucamonga, CA), and the Baerveldt Glaucoma Device (BGD) (Advanced Medical Optics, Santa Ana, CA). The AGV, with a venture-based flow-restrictive valve is helpful in minimizing postoperative hypotony and complications associated with hypotony, including flat anterior chamber, choroidal effusions, and suprachoroidal hemorrhage. However, there appears to be a high rate of encapsulation and hypertension associated with this device, and increased requirement of postoperative glaucoma medication use. The BGD, a non-valved device, requires early ligature of flow by the use of a suture restriction to allow adequate time for bleb formation. Although this can result in an initial post-operative hypertension phase, it results in less encapsulation and theoretically fewer postoperative glaucoma medications and better IOP control. However, the lack of a flow-restrictor and the large filtering surface area may result in a greater risk for hypotony related complications.
Although several studies comparing the AGV and BGD have been reported, they have all been retrospective, nonrandomized, small scale, and compare different patient populations. The results have been inconclusive and conflicting in evaluating the relative efficacy and characteristics of these two devices, and further research needs to be done in order to answer these questions.
Objective:
The Ahmed vs. Baerveldt (AVB) Study is the first multicenter prospective randomized clinical trial comparing the Ahmed FP7 valve and the Baerveldt-350 tube shunt glaucoma drainage devices. Primary outcome is surgical failure, a composite criteria evaluating the intraocular pressure lowering effect of the devices, complications of the surgery, treatments for complications, glaucoma medication use, and the preservation of visual acuity. Secondary outcomes will evaluate these variables individually, and any non-glaucoma related ocular pathology and required interventions.
AVB Study Manual:
An AVB Study Manual including the study design and protocol, standardized surgical technique, patient education and consent form, and data collection protocol was distributed to each clinical site. The contents of the manual received ethics approval by the Institutional Review Board (IRB) at the primary site.
Study Organization:
1. Investigator Committee (IC): Composed of study investigators and under the leadership of the Study Chair. The IC's responsibilities are defined below:
1. Designing the study protocol to ensure valid scientific method and proper ethical conduct.
2. Overseeing clinical centers to ensure that the protocol and ethical standards of the study are being upheld.
3. Overseeing the Data Acquisition \& Statistical Center to ensure that all practices are in accordance with those outlined in the protocol, and meet the ethical standards of the study.
4. Drafting and editing study documents critically for intellectual content and ethical considerations.
2. Clinical Centers (CC): Composed of study sites led by a Site Primary Investigator, whose responsibilities are defined below:
1. Enrolling patients in the study after determining eligibility and providing patient education. Informed consent must be written.
2. Ensuring that the study protocol and ethical standards of the study are upheld.
3. Ensuring that the study adheres to the policies set forth by the local Institutional/Ethical Review Board.
4. Acquiring study data and making it available to the Data Monitoring \& Statistics Committee.
3. Data Acquisition \& Statistical Center (DASC): Composed of Study Director and Study Statistician, with the following responsibilities:
1. Acquiring study data from each Clinical Center using the online study database (http://www.avsbstudy.com)
2. Statistical analysis of the study data.
Methods:
Patient Enrollment and Treatment Assignment:
Patients were recruited from 7 study sites by 10 surgeons. After patient eligibility and written informed consent was obtained by the Site PI, randomization to placement of an Ahmed FP7 valve or a Baerveldt-350 tube shunt was made by coin toss.
Pre-operative data collection:
The following data was collected in the 3 months prior to surgery: date of birth, gender, race, glaucoma diagnosis and etiology, past ocular history (diagnoses, surgical and laser procedures), best corrected visual acuity, intraocular pressure, glaucoma medication use, abnormal slit lamp findings, and abnormal fundus exam findings.
Surgical Procedure:
The surgical procedures used for the AVB Study are standardized, and any complications during surgery will be noted and defined.
Ahmed FP7 valve implantation:
A superior or inferior corneal traction suture with 8-0 Vicryl was placed for globe fixation as required. A 90-degree conjunctival peritomy was followed by blunt dissection to mobilize a fornix or limbus-based conjunctival flap over the area of intended device implantation. Non-preserved lidocaine 1% was injected under the conjunctival flap, posteriorly, and under the extraocular muscle bellies with a blunt cannula. Gentle cautery was used to obtain hemostasis.
The Ahmed Glaucoma Valve model FP-7 was primed with balanced salt solution, and placed in the intended quadrant. The plate was sutured to sclera 8-10mm posterior to the limbus with two 8-0 or 10-0 Nylon sutures.
A paracentesis was made if required, and a viscoelastic agent used to form the anterior chamber. A 22-gauge needle was used to create needle tract into the anterior chamber.
The tube was trimmed, and placed into the anterior chamber through the needle tract. The tube was attached to the sclera using a 10-0 Nylon suture if required. A sclera or corneal graft was placed over the tube and sutured to the sclera with 10-0 Nylon.
The conjunctival flap was closed with 8-0 or 10-0 Vicryl suture. At the conclusion of the case, Maxitrol ointment was placed on the eye. No patients were patched, although shields were given to patients. That day, patients were started on antibiotic and steroid eye drops. A cycloplegic was used as indicated.
Baerveldt-350 tube shunt implantation:
A superior or inferior corneal traction suture with 8-0 Vicryl was placed for globe fixation. A 90 to 120-degree conjunctival peritomy was followed by blunt dissection to mobilize a fornix or limbus-based conjunctival flap over the area of intended device implantation. Non-preserved lidocaine 1% was injected under the conjunctival flap, posteriorly, and under the extraocular muscle bellies with a blunt cannula. Gentle cautery was used to obtain hemostasis.
Both adjacent extraocular muscles were isolated using a muscle hook. 4-0 silk sutures were used for fixation if necessary.
The Baerveldt drainage device model BG101-350 was checked with balanced salt solution, and a 4-0 Nylon releasable intraluminal suture was placed. A 7-0 or 8-0 Vicryl ligature suture was placed around the tube. The plate was placed in the intended quadrant and under the muscle bellies. The plate was sutured to the sclera 8-12mm posterior to the limbus with two 8-0 or 10-0 Nylon sutures.
A paracentesis was made if it was required, and a viscoelastic agent used to form the anterior chamber. A 22-gauge needle was used to create needle tract into the anterior chamber. The tube was trimmed, and placed into the anterior chamber through the needle tract. The tube was attached to the sclera using a 10-0 Nylon suture if required. A sclera or corneal graft was placed over the tube and sutured to the sclera.
The conjunctival flap was closed with an 8-0 or 10-0 Vicryl suture. At the conclusion of the case, Atropine 1% drops and Maxitrol ointment was placed on the eye. No patients were patched, although shields were given to patients. On the day of surgery, patients were started on antibiotics and steroid eye drops. A cycloplegic agent was used as indicated.
Post-operative data collection:
Patients were seen post-operatively at a minimum of 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months 2 years, 3 years, 4 years and 5 years. Further visits were made as deemed necessary. At each visit, the following data was collected:
1. Intraocular pressure (IOP) by Goldmann Applanation Tonometry
2. Visual Acuity (VA) using a Snellen Chart or Low Vision Chart
3. Glaucoma Medication Use
4. Slit Lamp Biomicroscopy \& Ophthalmoscopy
5. Complications of Surgery
6. Interventions/Treatment of Complications
Outcome measures:
Based upon the pre-operative data and post-operative results, a study outcome will be assigned to each patient, as defined below:
Complete Success: (requires all of the following criteria)
1. IOP: 5 mmHg \<= IOP \<= 18 mmHg with a reduction in IOP of 20% or greater from baseline at every visit after 3 months.
2. Medications: No anti-glaucoma medications are required.
3. Complications: No vision threatening complications related to the implant/surgery.
4. Interventions: No additional glaucoma surgery or laser procedures are allowed.
5. Vision: No greater than a doubling of the mean angle of resolution (logMAR), which corresponds to approximately 2 Snellen lines.
Qualified Success: (requires all of the following criteria)
1. IOP: 5 mmHg \<= IOP \<= 18 mmHg with a reduction in IOP of 20% or greater from baseline, with no two consecutive visits after 3 months which do not meet this criterion.
2. Medications: Anti-glaucoma medications may be used.
3. Surgery/Complications: No vision threatening complications or surgery occurred after implantation of the GDD.
4. Interventions: Surgical and laser interventions to correct non-vision threatening complications of implant/surgery are allowed, but no additional glaucoma procedures are allowed.
5. Vision: No progression to no light perception.
Failure: (if any of the following criteria are met)
1. IOP: IOP \<5 mmHg or \>18 mmHg or reduction \<20% from pre-operative IOP in two consecutive visits after 3 months.
2. Surgery/Complications: Vision threatening complications or surgery required that is related to the implant. This includes severe choroidal effusions requiring drainage, suprachoroidal hemorrhage, endophthalmitis or malignant glaucoma requiring surgery.
3. Interventions: An additional glaucoma procedure is required (e.g. cyclodestruction, gold shunt implantation).
4. Vision: Progression to no light perception.
The use of a glaucoma drainage device (GDD) is indicated in cases of refractory glaucoma not responsive to conventional medication, laser and surgical therapy. Most of these patients are at high risk for surgical failure, with serious concomitant ocular and systemic diseases. GDD's are increasingly being used to obtain low target intraocular pressures (IOP) in patients who have failed antimetabolite trabeculectomy or have active neovascular glaucoma.
Since Molteno's original design, several drainage devices have become commercially available for implantation. Currently, the two most commonly used devices are the Ahmed Glaucoma Valve (AGV) (New World Medical, Inc., Rancho Cucamonga, CA), and the Baerveldt Glaucoma Device (BGD) (Advanced Medical Optics, Santa Ana, CA). The AGV, with a venture-based flow-restrictive valve is helpful in minimizing postoperative hypotony and complications associated with hypotony, including flat anterior chamber, choroidal effusions, and suprachoroidal hemorrhage. However, there appears to be a high rate of encapsulation and hypertension associated with this device, and increased requirement of postoperative glaucoma medication use. The BGD, a non-valved device, requires early ligature of flow by the use of a suture restriction to allow adequate time for bleb formation. Although this can result in an initial post-operative hypertension phase, it results in less encapsulation and theoretically fewer postoperative glaucoma medications and better IOP control. However, the lack of a flow-restrictor and the large filtering surface area may result in a greater risk for hypotony related complications.
Although several studies comparing the AGV and BGD have been reported, they have all been retrospective, nonrandomized, small scale, and compare different patient populations. The results have been inconclusive and conflicting in evaluating the relative efficacy and characteristics of these two devices, and further research needs to be done in order to answer these questions.
Objective:
The Ahmed vs. Baerveldt (AVB) Study is the first multicenter prospective randomized clinical trial comparing the Ahmed FP7 valve and the Baerveldt-350 tube shunt glaucoma drainage devices. Primary outcome is surgical failure, a composite criteria evaluating the intraocular pressure lowering effect of the devices, complications of the surgery, treatments for complications, glaucoma medication use, and the preservation of visual acuity. Secondary outcomes will evaluate these variables individually, and any non-glaucoma related ocular pathology and required interventions.
AVB Study Manual:
An AVB Study Manual including the study design and protocol, standardized surgical technique, patient education and consent form, and data collection protocol was distributed to each clinical site. The contents of the manual received ethics approval by the Institutional Review Board (IRB) at the primary site.
Study Organization:
1. Investigator Committee (IC): Composed of study investigators and under the leadership of the Study Chair. The IC's responsibilities are defined below:
1. Designing the study protocol to ensure valid scientific method and proper ethical conduct.
2. Overseeing clinical centers to ensure that the protocol and ethical standards of the study are being upheld.
3. Overseeing the Data Acquisition \& Statistical Center to ensure that all practices are in accordance with those outlined in the protocol, and meet the ethical standards of the study.
4. Drafting and editing study documents critically for intellectual content and ethical considerations.
2. Clinical Centers (CC): Composed of study sites led by a Site Primary Investigator, whose responsibilities are defined below:
1. Enrolling patients in the study after determining eligibility and providing patient education. Informed consent must be written.
2. Ensuring that the study protocol and ethical standards of the study are upheld.
3. Ensuring that the study adheres to the policies set forth by the local Institutional/Ethical Review Board.
4. Acquiring study data and making it available to the Data Monitoring \& Statistics Committee.
3. Data Acquisition \& Statistical Center (DASC): Composed of Study Director and Study Statistician, with the following responsibilities:
1. Acquiring study data from each Clinical Center using the online study database (http://www.avsbstudy.com)
2. Statistical analysis of the study data.
Methods:
Patient Enrollment and Treatment Assignment:
Patients were recruited from 7 study sites by 10 surgeons. After patient eligibility and written informed consent was obtained by the Site PI, randomization to placement of an Ahmed FP7 valve or a Baerveldt-350 tube shunt was made by coin toss.
Pre-operative data collection:
The following data was collected in the 3 months prior to surgery: date of birth, gender, race, glaucoma diagnosis and etiology, past ocular history (diagnoses, surgical and laser procedures), best corrected visual acuity, intraocular pressure, glaucoma medication use, abnormal slit lamp findings, and abnormal fundus exam findings.
Surgical Procedure:
The surgical procedures used for the AVB Study are standardized, and any complications during surgery will be noted and defined.
Ahmed FP7 valve implantation:
A superior or inferior corneal traction suture with 8-0 Vicryl was placed for globe fixation as required. A 90-degree conjunctival peritomy was followed by blunt dissection to mobilize a fornix or limbus-based conjunctival flap over the area of intended device implantation. Non-preserved lidocaine 1% was injected under the conjunctival flap, posteriorly, and under the extraocular muscle bellies with a blunt cannula. Gentle cautery was used to obtain hemostasis.
The Ahmed Glaucoma Valve model FP-7 was primed with balanced salt solution, and placed in the intended quadrant. The plate was sutured to sclera 8-10mm posterior to the limbus with two 8-0 or 10-0 Nylon sutures.
A paracentesis was made if required, and a viscoelastic agent used to form the anterior chamber. A 22-gauge needle was used to create needle tract into the anterior chamber.
The tube was trimmed, and placed into the anterior chamber through the needle tract. The tube was attached to the sclera using a 10-0 Nylon suture if required. A sclera or corneal graft was placed over the tube and sutured to the sclera with 10-0 Nylon.
The conjunctival flap was closed with 8-0 or 10-0 Vicryl suture. At the conclusion of the case, Maxitrol ointment was placed on the eye. No patients were patched, although shields were given to patients. That day, patients were started on antibiotic and steroid eye drops. A cycloplegic was used as indicated.
Baerveldt-350 tube shunt implantation:
A superior or inferior corneal traction suture with 8-0 Vicryl was placed for globe fixation. A 90 to 120-degree conjunctival peritomy was followed by blunt dissection to mobilize a fornix or limbus-based conjunctival flap over the area of intended device implantation. Non-preserved lidocaine 1% was injected under the conjunctival flap, posteriorly, and under the extraocular muscle bellies with a blunt cannula. Gentle cautery was used to obtain hemostasis.
Both adjacent extraocular muscles were isolated using a muscle hook. 4-0 silk sutures were used for fixation if necessary.
The Baerveldt drainage device model BG101-350 was checked with balanced salt solution, and a 4-0 Nylon releasable intraluminal suture was placed. A 7-0 or 8-0 Vicryl ligature suture was placed around the tube. The plate was placed in the intended quadrant and under the muscle bellies. The plate was sutured to the sclera 8-12mm posterior to the limbus with two 8-0 or 10-0 Nylon sutures.
A paracentesis was made if it was required, and a viscoelastic agent used to form the anterior chamber. A 22-gauge needle was used to create needle tract into the anterior chamber. The tube was trimmed, and placed into the anterior chamber through the needle tract. The tube was attached to the sclera using a 10-0 Nylon suture if required. A sclera or corneal graft was placed over the tube and sutured to the sclera.
The conjunctival flap was closed with an 8-0 or 10-0 Vicryl suture. At the conclusion of the case, Atropine 1% drops and Maxitrol ointment was placed on the eye. No patients were patched, although shields were given to patients. On the day of surgery, patients were started on antibiotics and steroid eye drops. A cycloplegic agent was used as indicated.
Post-operative data collection:
Patients were seen post-operatively at a minimum of 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months 2 years, 3 years, 4 years and 5 years. Further visits were made as deemed necessary. At each visit, the following data was collected:
1. Intraocular pressure (IOP) by Goldmann Applanation Tonometry
2. Visual Acuity (VA) using a Snellen Chart or Low Vision Chart
3. Glaucoma Medication Use
4. Slit Lamp Biomicroscopy \& Ophthalmoscopy
5. Complications of Surgery
6. Interventions/Treatment of Complications
Outcome measures:
Based upon the pre-operative data and post-operative results, a study outcome will be assigned to each patient, as defined below:
Complete Success: (requires all of the following criteria)
1. IOP: 5 mmHg \<= IOP \<= 18 mmHg with a reduction in IOP of 20% or greater from baseline at every visit after 3 months.
2. Medications: No anti-glaucoma medications are required.
3. Complications: No vision threatening complications related to the implant/surgery.
4. Interventions: No additional glaucoma surgery or laser procedures are allowed.
5. Vision: No greater than a doubling of the mean angle of resolution (logMAR), which corresponds to approximately 2 Snellen lines.
Qualified Success: (requires all of the following criteria)
1. IOP: 5 mmHg \<= IOP \<= 18 mmHg with a reduction in IOP of 20% or greater from baseline, with no two consecutive visits after 3 months which do not meet this criterion.
2. Medications: Anti-glaucoma medications may be used.
3. Surgery/Complications: No vision threatening complications or surgery occurred after implantation of the GDD.
4. Interventions: Surgical and laser interventions to correct non-vision threatening complications of implant/surgery are allowed, but no additional glaucoma procedures are allowed.
5. Vision: No progression to no light perception.
Failure: (if any of the following criteria are met)
1. IOP: IOP \<5 mmHg or \>18 mmHg or reduction \<20% from pre-operative IOP in two consecutive visits after 3 months.
2. Surgery/Complications: Vision threatening complications or surgery required that is related to the implant. This includes severe choroidal effusions requiring drainage, suprachoroidal hemorrhage, endophthalmitis or malignant glaucoma requiring surgery.
3. Interventions: An additional glaucoma procedure is required (e.g. cyclodestruction, gold shunt implantation).
4. Vision: Progression to no light perception.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Glaucoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ahmed FP7 Valve
Ahmed valve glaucoma drainage device implant for treatment of refractory glaucoma.
Group Type
ACTIVE_COMPARATOR
Ahmed FP7 Valve
Intervention Type
DEVICE
Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
Baerveldt-350 Tube
Baerveldt tube glaucoma drainage device implant for treatment of refractory glaucoma.
Group Type
ACTIVE_COMPARATOR
Baerveldt-350 Tube
Intervention Type
DEVICE
Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ahmed FP7 Valve
Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
Intervention Type
DEVICE
Baerveldt-350 Tube
Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
New World Medical
AGV FP7
Advanced Medical Optics
BG 101-350
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age greater than or equal to 18.
* Inadequately controlled glaucoma determined as intraocular pressure (IOP) greater than target, which has not responded to conventional medical and surgical therapy.
* Patients with significant conjunctival scarring or high-risk disease (active neovascular glaucoma) precluding antimetabolite trabeculectomy will be included in the study.
* Provide written informed consent to participate in the study.
* Inadequately controlled glaucoma determined as intraocular pressure (IOP) greater than target, which has not responded to conventional medical and surgical therapy.
* Patients with significant conjunctival scarring or high-risk disease (active neovascular glaucoma) precluding antimetabolite trabeculectomy will be included in the study.
* Provide written informed consent to participate in the study.
Exclusion Criteria
* Age less than 18.
* Patient will undergo an additional procedure at the time of glaucoma drainage device implantation (i.e. lensectomy, penetrating keratoplasty)
* No light perception vision.
* Patient has already been enrolled in the study in the contralateral eye.
* Patient is unwilling or unable to provide informed consent to participate in the study, or adhere to the study requirements including implant randomization and required follow-up visits.
* Patient will undergo an additional procedure at the time of glaucoma drainage device implantation (i.e. lensectomy, penetrating keratoplasty)
* No light perception vision.
* Patient has already been enrolled in the study in the contralateral eye.
* Patient is unwilling or unable to provide informed consent to participate in the study, or adhere to the study requirements including implant randomization and required follow-up visits.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glaucoma Research Society of Canada
OTHER
Sponsor Role
collaborator
Credit Valley EyeCare
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Panos G. Christakis
Study Director
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iqbal K Ahmed, MD
Role: STUDY_CHAIR
University of Toronto Department of Ophthalmology & Vision Sciences
Panos G Christakis, BS
Role: STUDY_DIRECTOR
Yale University
James C Tsai, MD
Role: PRINCIPAL_INVESTIGATOR
Yale Ophthalmology & Visual Science
Jeffrey W Kalenak, MD
Role: PRINCIPAL_INVESTIGATOR
Drs. Massaro & Kalenak, SC
Louis B Cantor, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Ophthalmology, Indiana University
Jeffrey A Kammer, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Ophthalmology and Visual Sciences: Vanderbilt University, School of Medicine
Paul J Harasymowycz, MD
Role: PRINCIPAL_INVESTIGATOR
University of Montreal: Department of Ophthalmology
Juan J Mura, MD
Role: PRINCIPAL_INVESTIGATOR
Clinic of Las Condes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eugene and Marilyn Glick Eye Institute
Indianapolis, Indiana, United States
Site Status
Vanderbilt Eye Institute
Nashville, Tennessee, United States
Site Status
Drs. Massaro and Kalenak
Milwaukee, Wisconsin, United States
Site Status
Credit ValleyEC
Toronto, Ontario, Canada
Site Status
Montreal Glaucoma Institute
Montreal, Quebec, Canada
Site Status
Clinic of Las Condes
Santiago, , Chile
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
Chile
References
Explore related publications, articles, or registry entries linked to this study.
Syed HM, Law SK, Nam SH, Li G, Caprioli J, Coleman A. Baerveldt-350 implant versus Ahmed valve for refractory glaucoma: a case-controlled comparison. J Glaucoma. 2004 Feb;13(1):38-45. doi: 10.1097/00061198-200402000-00008.
Reference Type
BACKGROUND
Wang JC, See JL, Chew PT. Experience with the use of Baerveldt and Ahmed glaucoma drainage implants in an Asian population. Ophthalmology. 2004 Jul;111(7):1383-8. doi: 10.1016/j.ophtha.2003.11.005.
Reference Type
BACKGROUND
Tsai JC, Johnson CC, Dietrich MS. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome. Ophthalmology. 2003 Sep;110(9):1814-21. doi: 10.1016/S0161-6420(03)00574-8.
Reference Type
BACKGROUND
Tsai JC, Johnson CC, Kammer JA, Dietrich MS. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma II: longer-term outcomes from a single surgeon. Ophthalmology. 2006 Jun;113(6):913-7. doi: 10.1016/j.ophtha.2006.02.029.
Reference Type
BACKGROUND
Goulet RJ 3rd, Phan AD, Cantor LB, WuDunn D. Efficacy of the Ahmed S2 glaucoma valve compared with the Baerveldt 250-mm2 glaucoma implant. Ophthalmology. 2008 Jul;115(7):1141-7. doi: 10.1016/j.ophtha.2007.10.034. Epub 2007 Dec 27.
Reference Type
BACKGROUND
Coleman AL, Hill R, Wilson MR, Choplin N, Kotas-Neumann R, Tam M, Bacharach J, Panek WC. Initial clinical experience with the Ahmed Glaucoma Valve implant. Am J Ophthalmol. 1995 Jul;120(1):23-31. doi: 10.1016/s0002-9394(14)73755-9.
Reference Type
BACKGROUND
Huang MC, Netland PA, Coleman AL, Siegner SW, Moster MR, Hill RA. Intermediate-term clinical experience with the Ahmed Glaucoma Valve implant. Am J Ophthalmol. 1999 Jan;127(1):27-33. doi: 10.1016/s0002-9394(98)00394-8.
Reference Type
BACKGROUND
Krishna R, Godfrey DG, Budenz DL, Escalona-Camaano E, Gedde SJ, Greenfield DS, Feuer W, Scott IU. Intermediate-term outcomes of 350-mm(2) Baerveldt glaucoma implants. Ophthalmology. 2001 Mar;108(3):621-6. doi: 10.1016/s0161-6420(00)00537-6.
Reference Type
BACKGROUND
Lloyd MA, Baerveldt G, Fellenbaum PS, Sidoti PA, Minckler DS, Martone JF, LaBree L, Heuer DK. Intermediate-term results of a randomized clinical trial of the 350- versus the 500-mm2 Baerveldt implant. Ophthalmology. 1994 Aug;101(8):1456-63; discussion 1463-4. doi: 10.1016/s0161-6420(94)31152-3.
Reference Type
BACKGROUND
Britt MT, LaBree LD, Lloyd MA, Minckler DS, Heuer DK, Baerveldt G, Varma R. Randomized clinical trial of the 350-mm2 versus the 500-mm2 Baerveldt implant: longer term results: is bigger better? Ophthalmology. 1999 Dec;106(12):2312-8. doi: 10.1016/S0161-6420(99)90532-8.
Reference Type
BACKGROUND
Nouri-Mahdavi K, Caprioli J. Evaluation of the hypertensive phase after insertion of the Ahmed Glaucoma Valve. Am J Ophthalmol. 2003 Dec;136(6):1001-8. doi: 10.1016/s0002-9394(03)00630-5.
Reference Type
BACKGROUND
Law SK, Nguyen A, Coleman AL, Caprioli J. Comparison of safety and efficacy between silicone and polypropylene Ahmed glaucoma valves in refractory glaucoma. Ophthalmology. 2005 Sep;112(9):1514-20. doi: 10.1016/j.ophtha.2005.04.012.
Reference Type
BACKGROUND
Ayyala RS, Harman LE, Michelini-Norris B, Ondrovic LE, Haller E, Margo CE, Stevens SX. Comparison of different biomaterials for glaucoma drainage devices. Arch Ophthalmol. 1999 Feb;117(2):233-6. doi: 10.1001/archopht.117.2.233.
Reference Type
BACKGROUND
Ayyala RS, Michelini-Norris B, Flores A, Haller E, Margo CE. Comparison of different biomaterials for glaucoma drainage devices: part 2. Arch Ophthalmol. 2000 Aug;118(8):1081-4. doi: 10.1001/archopht.118.8.1081.
Reference Type
BACKGROUND
Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK 2nd, Heuer DK, Brandt JD; Tube Versus Trabeculectomy Study Group. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005 Aug;140(2):275-87. doi: 10.1016/j.ajo.2005.03.031.
Reference Type
BACKGROUND
Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol. 2007 Jan;143(1):23-31. doi: 10.1016/j.ajo.2006.07.022. Epub 2006 Sep 1.
Reference Type
BACKGROUND
Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. Am J Ophthalmol. 2007 Jan;143(1):9-22. doi: 10.1016/j.ajo.2006.07.020. Epub 2006 Sep 1.
Reference Type
BACKGROUND
Christakis PG, Tsai JC, Zurakowski D, Kalenak JW, Cantor LB, Ahmed II. The Ahmed Versus Baerveldt study: design, baseline patient characteristics, and intraoperative complications. Ophthalmology. 2011 Nov;118(11):2172-9. doi: 10.1016/j.ophtha.2011.05.003. Epub 2011 Sep 9.
Reference Type
RESULT
Christakis PG, Kalenak JW, Zurakowski D, Tsai JC, Kammer JA, Harasymowycz PJ, Ahmed II. The Ahmed Versus Baerveldt study: one-year treatment outcomes. Ophthalmology. 2011 Nov;118(11):2180-9. doi: 10.1016/j.ophtha.2011.05.004. Epub 2011 Sep 1.
Reference Type
RESULT
Christakis PG, Tsai JC, Kalenak JW, Zurakowski D, Cantor LB, Kammer JA, Ahmed II. The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology. 2013 Nov;120(11):2232-40. doi: 10.1016/j.ophtha.2013.04.018. Epub 2013 Jun 21.
Reference Type
RESULT
Christakis PG, Kalenak JW, Tsai JC, Zurakowski D, Kammer JA, Harasymowycz PJ, Mura JJ, Cantor LB, Ahmed II. The Ahmed Versus Baerveldt Study: Five-Year Treatment Outcomes. Ophthalmology. 2016 Oct;123(10):2093-102. doi: 10.1016/j.ophtha.2016.06.035. Epub 2016 Aug 17.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GRSC-2005
Identifier Type: OTHER
Identifier Source: secondary_id
CVEC-AVB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Baerveldt Versus ClearPath Comparison Study
NCT04468633
COMPLETED
NA
Ahmed Glaucoma Valve and Single-Plate Molteno Implants in Treatment of Refractory Glaucoma
NCT00971061
COMPLETED
PHASE3
Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves
NCT01883856
COMPLETED
NA
Ahmed Glaucoma Valve Implantation; Graft-Free Short Tunnel Small Flap Versus Scleral Patch Graft
NCT03551834
UNKNOWN
PHASE1/PHASE2
Results of Different Location of Ahmed Glaucoma Valve Implantation in Refractory Glaucoma, Superior Versus Inferior
NCT00628173
COMPLETED
NA
The Asia Primary Tube Versus Trab (TVT) Study
NCT03274024
UNKNOWN
NA
Paul Glaucoma Implant Versus Ahmed Glaucoma Valve in Childhood Glaucoma
NCT05797350
UNKNOWN
NA
Efficacy and Safety of Posterior Chamber Glaucoma Drainage Device
NCT07003685
ENROLLING_BY_INVITATION
NA
Intraluminal Stenting Versus External Ligation of Ahmed Glaucoma Valve
NCT04508881
COMPLETED
NA
Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves
NCT01535768
UNKNOWN
PHASE4
Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation
NCT01814514
UNKNOWN
PHASE2
Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma
NCT01494974
UNKNOWN
PHASE4
Early Evaluation of the Beacon Aqueous Microshunt in Patients Refractory to Drug Therapy in the European Union
NCT03634319
TERMINATED
NA
Re-Trabeculectomy Versus Ahmed Glaucoma Valve Implantation in Secondary Surgical Management of Patients With Refractory Glaucoma
NCT01633775
COMPLETED
Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma
NCT02260219
TERMINATED
NA
The Outcome of Ahmed Glaucoma Valve in Difficult Glaucoma Cases
NCT04214847
COMPLETED
NA
SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma
NCT00382395
SUSPENDED
PHASE3
The Results of Ahmed Valve Operations
NCT00193960
UNKNOWN
Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma
NCT04072016
TERMINATED
NA
Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular Glaucoma
NCT05316142
ACTIVE_NOT_RECRUITING
NA
Baerveldt Plate Area Comparison (BPAC)
NCT01159314
TERMINATED
NA
Trabeculectomy With MMC Versus Ahmed Glaucoma Implant for Treatment of Pediatric Aphakic Glaucoma
NCT00371072
COMPLETED
PHASE2/PHASE3
Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves and Second Trabeculectomy in Glaucoma Patients
NCT00665756
UNKNOWN
NA
Aqueous Dynamics and Glaucoma Surgeries
NCT02839590
UNKNOWN